ANALYSIS
Saurav Datta looks at the various issues surrounding Price Control of Drugs.
Pharmaceutical Prices Regulation- the government’s deception needs to be called out.
“We cannot afford to let them die those who cannot afford to live”
It would be Utopian to wish this was embraced as a motto by both the State and the pharmaceutical industry (now bestowed with the monicker “Big Pharma”). The bitter fight over Obama’s universal health insurance scheme, and the way it created a bipolar schism of a magnitude not seen since the Civil War bares ample testimony to the fact that implementation of “health for all” is regarded as a blistering attack on liberty, of individuals and corporations (in the eyes of the law, they are also individuals, what is known as juristic persons).
The US Supreme Court, by a narrow margin, upheld the constitutionality of this scheme, but the embers of spirited resentment, and determined efforts to derail it, have not lost a bit of their glow.
The situation is not so dire in India, though the debate in the run-up to the Supreme Court’s judgement in the Novartis case did demonstrate how fraught the situation, in all likelihood, shall become in the near future. The tug-of-war is essentially between the pharmaceutical companies’ right to levels of profitability they consider just, and the millions of people’s right to access healthcare. It is a matter of excruciating irony that a theory of rights (of corporations, to function, thrive and prosper with liberty- minimal, preferably nil government control) is being pitched against a theory of justice (also known as the Rawlsian paradigm ) but that is inevitable in a mercenary world, one might think.
Globally, a blazing battle rages on regarding governmental curbs on Big Pharma’s intellectual property rights so as to fulfill the obligation of making the human right to health a reality. A smaller battle, which has not scorched the media terrain yet, is against government regulation of pharmaceutical pricing. Developing countries form the most common battleground, though it would be too facile to assume that equitable access to health and healthcare is a functional reality in developed countries too.
A commonly fired torpedo against such controls is the argument centred on innovation – millions are spent on R &D of drugs, and price curbs will dry up research, thereby having a pernicious effect on patients. A fitting riposte to that would entail going into the details of the economics of intellectual property rights, which is not our present purpose (though, this could come in handy as reference). Rather, here in India, where every policy “debate” is characterised by tunnel vision and vociferous broadcast of binaries, the truth, and the devil, which lurks in the minute details, often escape scrutiny. The Bhagwati- Sen “slugfest” would be an apt example. The war of words and missiles of rhetoric being fired over the proposed Drug Prices Control Order (DPCO) seem to be following this same trajectory- towards a farce.
Price regulation of drugs, especially essential medicines and life-saving drugs are not a new phenomenon in India, although there has been a substantial whittling down, perhaps to remain onboard the liberalization juggernaut. For instance, in the DPCO 1995, the number of drugs subjected to such control was brought down to 74 from 166 in 1987. In 2002, the NPAA (National Pharmaceutical Pricing Authority) recommended a further dilution, which was carried out in earnest.
Before anyone screeches from the burlap- that such regulation is the ominous continuation of the sinister licence permit Raj , it must be noted that “regulation” and “control” are not coterminous. In control there is no freedom, in regulation there is freedom but subject to reasonable restrictions in the public interest. It must also be noted that prices of all drugs are not subjected to “control”
What is the government’s rationale for such regulation? It is essentially dependent upon the nature of the market. Because the Indian pharmaceutical market is oligopolistic in nature, where consumer sovereignty remains a distant mirage and information-asymmetry drives supplier-induced demand, it is a veritable private sector oligarchy. The problem is compounded by the fact that pharma companies’ loyalty to profitability is best described by Churchill’s phrase “as loyal as a leech.” Nothing wrong in that, except for the fact that in a country where inequitable access to healthcare is endemic, putatively laudable “enterprise” becomes nothing but demonic profiteering.
Therefore, an NLEM- National List of Essential Medicines) is drawn up, on the basis of three critical underlying principles- Cost, safety and efficacy.
The National Pharmaceuticals Pricing Policy 2012 replaced the Drugs (Price Control) Order, 1994 that currently monitors and regulates prices of essential medicines in the country. Under this, the Drug Price Control Order 2013, which came into effect on July 29, lowered prices of 348 essential drugs so as to bring succor to those in dire need. Big Pharma has cried murder and rushed to the Delhi High Court, which has since granted a stay on its implementation. What is lost in the tendentious account of the pros and cons of the impugned DPCO is the government’s sleight of hand.
It is an inescapable reality of present times that much-touted benevolence and care of the government usually camouflages malevolent mendacity. The NPPP 2012 achieves the same purpose by replacing CBP (Cost Based Pricing) with MBP (Market Based Pricing).
In previous regimes, drug prices were regulated at two levels:
Thus, it was ensured no one was better off at the cost of another, that is, equitable access to healthcare (or a semblance of it, at least) was maintained. But now, with the MBP, it is a foregone conclusion that equity would be buried for good. This is because “The Invisible Hand” of the market, and an oligopolistic one at that, brushes away, in quite an insentient manner, everyone who lacks the capacity and capability to pay up.
Hence, instead of cheering the dutiful government and berating Big Pharma for its avarice, one might do well to train the guns on the government’s priority to safeguard the pharmaceutical industry. The human right to equitable access to healthcare and health is too precious to be expended in bickering over rhetoric.
Meet Swati Singh, wife of BJP's Parvesh Verma, who defeated Arvind Kejriwal by 4089 votes
Meet man, son of world’s richest woman, he is set to take over Rs 1642000 crore empire as...
SHOCKING! Bride's family cancels wedding at last moment over groom's low...
Nita Ambani, Shloka Mehta stun in gorgeous sarees at Priyanka Chopra's brother wedding
Meet Trisha and Sanidhi, daughters of BJP's Parvesh Verma, who defeated Arvind Kejriwal
New entrant in grocery quick-commerce, ready to compete with industry giants
Transforming the news and media industry with Generative AI: Expert insights by Sanjay Jain
Dr Tanvi Tijoriwala, ND shedsputs light on balancing skin barrier during rising temperatures
How PM Modi's magic shattered Arvind Kejriwal and his third-term hope in Delhi?
Ahmedabad: Fire breaks out at Sabarmati bullet train station, check details
Meet Sunita Kejriwal, Arvind Kejriwals's wife, who was former IRS officer, met him during...
BIG blow for Meta employees, Mark Zuckerberg's company to layoff employees from..., reason is...
Amitabh Bachchan sparks major concern among fans with cryptic post, writes 'time to go'
Taylor Swift 'feels used' by Blake Lively, wishes she didn't drag her into Justin Baldoni case
Meet IAS officer who failed five times before cracking UPSC exam, cleared in 6th attempt with AIR...
Delhi Election Result 2025 Live Updates: Check full list of winners and losers in Delhi elections
Who is Kabir Bahia, Kriti Sanon's rumoured boyfriend who hid his face from paps
Delhi Election Result 2025: AAP's Arvind Kejriwal vs BJP's Parvesh Verma; key contests to watch out
Bank holidays in February 2025: Check if banks are open or closed on February 8?
Cristiano Ronaldo sends heartfelt retirement message to former Real Madrid teammate Marcelo Viera
Jeet Adani, Diva Shah are now married! Here's why their wedding was more than a mere celebration
IIT-BHU student gets highest package of Rs..., average package in 2025 is...
Music composer Anu Malik sells two Mumbai flats in Santacruz West for Rs..., co-owner is...
Jeet Adani and Diva Shah are now married; video of varmala ceremony goes viral, WATCH
Jeet Adani-Diva Shah wedding: Gautam Adani shares first pics of son's wedding, see here
Can Kejriwal win prestige battle? What are the key factors that dominated Delhi assembly polls 2025?
Subhash Ghai makes big investment, buys plush 4BHK apartment in Mumbai for...
Metovalex App Review 2025: Legit Or Scam Trading AI? - Real User Facts!
Deepinder Goyal's Zomato rebranded Eternal: Everyone has the same question
Thief gifts Rs 3cr house to girlfriend, everyone shocked after...
Who is Meghnad S? YouTuber and journalist who contested Delhi assembly polls 2025 from...
Does Sanya Malhotra's 'Mrs' promote a no-marriage culture among women?
BIG blow to Sundar Pichai as Google loses Rs 17501260000000 due to…
Caring for Ageing Parents? Essential tips to manage health, finances, and well-being
Meet Gautam Adani’s daughter-in-law Paridhi Adani: Know about her assets, career, family, and more
Jeet Adani-Diva Shah wedding: Inside pics from Gautam Adani's son's wedding festivity
Why has Premanand Maharaj stopped his morning yatras at 2 am?
Sonu Sood BREAKS SILENCE on arrest warrant against him in fraud case: 'It is sad that celebs...'
Akshata Murty once confronted her father and Infosys co-founder Narayana Murthy: 'My real dad is...'
Meet Alexis Wilkins, Trump's FBI chief pick Kash Patel's 'mystery girlfriend,' her profession is...
Fire breaks out at Mahakumbh Nagar camp, officials say no casualties reported so far
Who is Mohini Mohan Datta, mystery man set to get Rs 500 crore through Ratan Tata's will?